Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Semiglazov Vf et al.|Annals of Oncology|2021Cited by 724
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|European Journal of Cancer|2021Cited by 42
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).Valentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Journal of Clinical Oncology|2020Cited by 3
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus projectStefania Gori, Paolo Tralongo, Fiorenza De Rose et al.|Cancer Treatment Reviews|2024Cited by 2
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancerValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|IRIS UNIMORE (University of Modena and Reggio Emilia)|2020Cited by 0